Teriflunomide is contraindicated in pregnant women or women of childbearing age due to the risk of teratogenicity. Teriflunomide is also contraindicated in severe hepatic impairment due to reports of hepatotoxicity, hepatic failure, and death.
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Teriflunomide. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide. |
| Peginterferon alfa-2a | The risk or severity of liver damage can be increased when Peginterferon alfa-2a is combined with Teriflunomide. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Teriflunomide. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Teriflunomide. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teriflunomide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Teriflunomide. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Teriflunomide. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Teriflunomide. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Teriflunomide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Teriflunomide. |
| Gemtuzumab ozogamicin | The risk or severity of liver damage can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Teriflunomide. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Teriflunomide. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Teriflunomide. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Teriflunomide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Teriflunomide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Teriflunomide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Teriflunomide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Teriflunomide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Teriflunomide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teriflunomide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Teriflunomide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Teriflunomide. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teriflunomide. |
| Interferon alfa-2b | The risk or severity of liver damage can be increased when Interferon alfa-2b is combined with Teriflunomide. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Teriflunomide. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Teriflunomide. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Teriflunomide. |
| Cladribine | The excretion of Cladribine can be decreased when combined with Teriflunomide. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Teriflunomide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Teriflunomide. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Teriflunomide. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Teriflunomide. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Teriflunomide. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Teriflunomide. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Teriflunomide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Teriflunomide. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Teriflunomide. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Teriflunomide. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Teriflunomide. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Teriflunomide. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Teriflunomide. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Teriflunomide. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Teriflunomide. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Teriflunomide. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Teriflunomide. |
| Epirubicin | The risk or severity of liver damage can be increased when Epirubicin is combined with Teriflunomide. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Teriflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Teriflunomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Teriflunomide. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Teriflunomide. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Teriflunomide. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teriflunomide. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Teriflunomide. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Teriflunomide. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Teriflunomide. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Teriflunomide. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Teriflunomide. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Teriflunomide. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Teriflunomide. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Teriflunomide. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Teriflunomide. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Teriflunomide. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Teriflunomide. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Teriflunomide. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Teriflunomide. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Teriflunomide. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Teriflunomide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Teriflunomide. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Teriflunomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Teriflunomide. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Teriflunomide. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Teriflunomide. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Teriflunomide. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Teriflunomide. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Teriflunomide. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Teriflunomide. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Teriflunomide. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Teriflunomide. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Teriflunomide. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Teriflunomide. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Teriflunomide. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Teriflunomide. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Teriflunomide. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Teriflunomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Teriflunomide. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Teriflunomide. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Teriflunomide. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Teriflunomide. |
| Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Teriflunomide. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Teriflunomide. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Teriflunomide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Teriflunomide. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Ifosfamide is combined with Teriflunomide. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Teriflunomide. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Teriflunomide. |